Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Daiichi Sankyo
Daiichi Sankyo
I-Mab Biopharma US Limited
Merus B.V.
Pfizer
Amgen
MacroGenics
Celldex Therapeutics
Shenzhen Hornetcorn Bio-technology Company, LTD
FeRx